TECNALIA SERBIA DOO BEOGRAD

Their core work

TECNALIA Serbia is the Belgrade-based subsidiary of TECNALIA, one of Europe's largest applied research organizations headquartered in Spain. The Serbian office contributes specialized expertise in biomedical device development, nanotechnology-enabled surfaces, and wearable sensor systems to large EU research consortia. Their work spans from stretchable biomedical electrodes and microfluidic device upscaling to brain-computer interfaces and health monitoring in extreme environments. They primarily serve as a third-party contributor or technical partner, providing materials testing, device validation, and quality management capabilities.

What they specialise in

How they've shifted over time

TECNALIA Serbia's H2020 portfolio spans a narrow window (2019–2020 start dates), so evolution is subtle but visible. Early projects centered on wearable biomedical electrodes and nanotechnology safety testing for medical devices. By 2020, the focus broadened to include microfluidic device upscaling, brain-computer interfaces, and health monitoring in extreme environments — indicating a shift from component-level research toward more applied, system-level work with clearer paths to market.

Moving from biomedical component research toward integrated human-machine systems and manufacturing scale-up, suggesting growing interest in translating lab prototypes into products.

How they like to work

TECNALIA Serbia never coordinates projects — they join as a third party (4 times) or participant (3 times), typically contributing specialized technical tasks within large consortia. With 92 unique partners across 23 countries, their network is broad but largely inherited from the major consortia they join rather than built through repeated bilateral partnerships. Working with them means accessing a reliable technical contributor that fits into established consortium structures without demanding a leadership role.

Connected to 92 unique partners across 23 countries through participation in mid-to-large research consortia. Their network is pan-European with no strong geographic clustering, reflecting the broad reach of the TECNALIA parent organization.

What sets them apart

As a Serbian subsidiary of Spain's TECNALIA research center, they offer an unusual combination: the credibility and technical depth of a top-tier European research organization with a presence in the Western Balkans. This makes them a valuable partner for consortia seeking geographic diversity or Widening Country participation. Their niche at the intersection of nanotechnology, biomedical devices, and manufacturing scale-up is uncommon for a Serbia-based entity.

Highlights from their portfolio

• SIXTHSENSE
  Largest single funding (EUR 401,500) — smart health monitoring with biofeedback for extreme environments, bridging their biomedical expertise with security applications.
• NextGenMicrofluidics
  Longest-running project (2020–2025) focused on upscaling nano-enabled microfluidic devices from lab to roll-to-roll production — their most manufacturing-oriented work.
• NIMA
  Represents a strategic expansion into neurotechnology and brain-computer interfaces for motor augmentation, a significant departure from their biomedical electrode core.